Effects of metformin treatment on serum levels of C-reactive protein and interleukin-6 in women with polycystic ovary syndrome: a meta-analysis A PRISMA-compliant article
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Metformin is effective for the treatment of polycystic ovary syndrome (PCOS), but conflicting results regarding its impact on serum levels of C-reactive protein (CRP) and interleukin-6 (IL-6) in women with PCOS have been reported. To provide high-quality evidence about the effect of treatment with metformin on CRP and IL-6 in PCOS, relevant studies that assessed the serum levels of CRP and IL-6 in women with PCOS receiving metformin treatment were reviewed and analyzed. METHODS: A literature search was conducted in the Science Citation Index, PubMed, Embase, and Cochrane Library databases, and personal contact was made with the authors. Random-effects model was used to estimate the standardized mean differences (SMDs) with 95% confidence intervals (95% CIs). To ensure synthesis of the best available evidence, subgroup analysis, sensitivity analysis, meta-regression analysis, and publication bias were performed. RESULTS: Of 216 studies identified, 20 were included in the meta-analysis (7 prospective, nonrandomized studies, and 13 randomized control trials). Data suggest that serum levels of CRP were decreased after metformin treatment in PCOS patients with an SMD (95% CI) of -0.86 [-1.24 to -0.48] and P = .000 (random-effects). However, significant heterogeneity was detected across studies (I = 84.6% and P = .000). Unfortunately, the sources of heterogeneity were not found by subgroup analysis and meta-regression analysis. Serum IL-6 concentrations were not significantly changed after metformin treatment in PCOS with an SMD (95% CI) of -0.48 [-1.26 to 0.31] and P > .05 (random-effects). Significant heterogeneity was also detected across studies (I = 90.9% and P = .000). The subgroup analysis suggested that treatment-related reductions in serum IL-6 levels were significantly correlated with BMI, whereas the sources of heterogeneity were not found. In addition, we noticed that metformin treatment could decrease BMI in the CRP and IL-6 related studies (SMD = -0.45, 95% CI: -0.68 to -0.23; SMD = -0.44, 95% CI: -0.73 to -0.16). CONCLUSION: This meta-analysis showed a significant decrease of serum CRP levels, especially in obese women, but no significant changes in IL-6 levels after metformin treatment in women with PCOS. In general, the data support that early metformin therapy may ameliorate the state of chronic inflammation in women with PCOS. Considering the obvious heterogeneity reported in the literature, further well-designed investigations with larger samples are needed to ascertain the long-term effects of metformin on chronic inflammation in PCOS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S. E., Legro, R. S., Lizneva, D., Natterson-Horowtiz, B., Teede, H. J., & Yildiz, B. O. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.57 · Cited by 2,005
Norman, R. J., Dewailly, D., Legro, R. S., & Hickey, T. E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61345-2 · Cited by 1,360
Metformin and inflammation: its potential Beyond glucose-lowering effect
Saisho, Y. (2015) · Endocrine, Metabolic & Immune Disorders-Drug Targets · doi:10.2174/1871530315666150316124019 · Cited by 450
Spritzer, P. M., Lecke, S. B., Satler, F., & Morsch, D. M. (2015) · Reproduction · doi:10.1530/rep-14-0435 · Cited by 330
Dregan, A., Charlton, J., Chowienczyk, P., & Gulliford, M. C. (2014) · Circulation · doi:10.1161/circulationaha.114.009990 · Cited by 303
Elkind-Hirsch, K., Marrioneaux, O., Bhushan, M., Vernor, D., & Bhushan, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0115 · Cited by 276
Hoeger, K., Davidson, K., Kochman, L., Cherry, T., Kopin, L., & Guzick, D. S. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0461 · Cited by 256
Asemi, Z., & Esmaillzadeh, A. (2015) · Hormone and Metabolic Research · doi:10.1055/s-0034-1376990 · Cited by 134
Shorakae, S., Teede, H., de Courten, B., Lambert, G., Boyle, J., & Moran, L. (2015) · Seminars in Reproductive Medicine · doi:10.1055/s-0035-1556568 · Cited by 115
Esfahanian, F., Zamani, M. M., Heshmat, R., & Moini nia, F. (2013) · Journal of obstetrics and gynaecology research · doi:10.1111/j.1447-0756.2012.02051.x · Cited by 38
Cited by
Løvvik, T. S., Carlsen, S. M., Salvesen, Ø., Steffensen, B., Bixo, M., Gómez-Real, F., Lønnebotn, M., Hestvold, K. V., Zabielska, R., Hirschberg, A. L., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30002-6 · Cited by 176
Anti-inflammatory properties of antidiabetic drugs: a “promised land” in the COVID-19 era?
Katsiki, N., & Ferrannini, E. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107723 · Cited by 91
“6%).(25) Data on the effects ofmetformin on IL-6 and ferritin are limited.”
The use of metformin in women with polycystic ovary syndrome: an updated review
Notaro, A. L. G., & Neto, F. T. L. (2022) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-022-02429-9 · Cited by 83
“Similarly, two MAs that assessed the use of MT in nonpregnant women with PCOS showed that its use improved clinical parameters such as BMI, waist-hip ratio, and diastolic blood pressure, but without impact on metabolic parameters and endocrine disorders [26, 27].”
Background
Metadata
- Authors
- Wang, J., Zhu, L., Hu, K., Tang, Y., Zeng, X., Liu, J., & Xu, J.
- Venue
- Medicine
- Published
- 2017-09
- Volume
- 96
- Issue
- 39
- Pages
- e8183
- ISSN
- 0025-7974 (ISSN-L)
- OpenAlex
- W2950495834
- Cited by
- 52
- References
- 10
- FWCI
- 2.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of metformin treatment on serum levels of C-reactive protein and interleukin-6 in women with polycystic ovary syndrome: a meta-analysis A PRISMA-compliant article. https://app.cochat.ai/papers/10.1097/md.0000000000008183
- The paper
- Wang, J., Zhu, L., Hu, K., Tang, Y., Zeng, X., Liu, J., & Xu, J. (2017). Effects of metformin treatment on serum levels of C-reactive protein and interleukin-6 in women with polycystic ovary syndrome: a meta-analysis A PRISMA-compliant article. Medicine. https://doi.org/10.1097/md.0000000000008183
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.